...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Progress in Artificial Intelligence >Dissimilar Effects of Anagliptin and Sitagliptin on Lipoprotein Subclass in Standard or Strong Statin-Treated Patients with Type-2 Diabetes Mellitus: A Subanalysis of the REASON (Randomized Evaluation of Anagliptin versus Sitagliptin on Low-Density LipoproteiN Cholesterol in Diabetes) Trial
【24h】

Dissimilar Effects of Anagliptin and Sitagliptin on Lipoprotein Subclass in Standard or Strong Statin-Treated Patients with Type-2 Diabetes Mellitus: A Subanalysis of the REASON (Randomized Evaluation of Anagliptin versus Sitagliptin on Low-Density LipoproteiN Cholesterol in Diabetes) Trial

机译：Anagliptin和SitaGliptin对2型糖尿病患者脂蛋白亚类对脂蛋白亚类的不同影响MELLITUS：对糖尿病低密度脂蛋白胆固醇对SINAGLIPTIN对SITAGLIPTIN的随机评价）试验的药物分析

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The effects of antidiabetic agents on lipoprotein subclasses are assumed to be pivotal, but this assumption has not been studied. We evaluated lipoprotein subclasses in patients, randomly selected from REASON (Randomized Evaluation of Anagliptin versus Sitagliptin On low-density lipoproteiN cholesterol in diabetes) Trial participants, with type-2 diabetes treated with either anagliptin or sitagliptin. We measured total cholesterol (TC) and triglycerides (TG) in 4 (chylomicron (CM), very low-density lipoprotein (VLDL), low density lipoprotein (LDL), and high-density lipoprotein (HDL)) lipoprotein classes and 20 (2 CM, 5 VLDL, 6 LDL, and 7 HDL) lipoprotein subclasses. Between 0 and 52 weeks, TC and TG in lipoprotein and the lipoprotein subclass were distributed differently in patients treated with anagliptin and sitagliptin. The preferable changes in TC and TG levels were observed dominantly in the anagliptin-treated group under standard statin therapy, but the benefits were observed in both the anagliptin- and sitagliptin-treated groups, at least partially under strong statin therapy. In future studies, the atherogenic properties of lipoprotein subclasses might be considered when employing antidiabetic dipeptidyl peptidase-4 (DPP-4) inhibitors, especially in patients with type-2 diabetes who are at risk of atherosclerotic cardiovascular disease (ASCVD) or are undergoing statin treatment.
机译：假设抗糖尿病药物对脂蛋白亚类的影响是关键的，但这种假设尚未研究。我们评估患者的脂蛋白亚类，随机选择（随机评估Anaglitin与SITAGLIPTIN在糖尿病的低密度脂蛋白胆固醇上）试验参与者，用ANAGLIPTIN或SITAGLIPTIN治疗2型糖尿病。我们在4中测量总胆固醇（Tc）和甘油三酯（Tg）（Chylomicron（cm），非常低密度脂蛋白（VLDL），低密度脂蛋白（LDL），以及高密度脂蛋白（HDL））脂蛋白类和20（ 2厘米，5 VLDL，6 LDL和7个HDL）脂蛋白亚类。在用Anagliptin和SitaGlittin治疗的患者中，在脂蛋白和脂蛋白和脂蛋白亚类中的TC和TG分布不同。在标准沙特汀治疗下，在Anagliptin治疗组中占据了Tc和Tg水平的优选变化，但在血管素和SitaGliptin治疗的基团中，至少部分地在强大的他汀类药物治疗中观察到益处。在未来的研究中，当使用抗糖尿病二肽基肽酶-4（DPP-4）抑制剂时，可能考虑脂蛋白亚类的动脉粥样硬化性能，尤其是在患有动脉粥样硬化心血管疾病（ASCVD）的风险或正在进行他汀类药物的2型糖尿病患者中治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号